RELATED CONTENT
iSchemaView announced the company’s co-founder Gregory Albers, M.D., has received the Distinguished Clinical Research Achievement Award, presented by the Clinical Research Forum. The Distinguished Clinical Research Achievement Awards are presented to the top two studies that show creativity, innovation, or a novel approach that demonstrates an immediate impact on the health and well-being of patients.
March 19, 2019 
iSchemaView announced the release of RAPID Angio, a complete neuroimaging solution for the angiography suite that integrates iSchemaView’s RAPID software with syngo DynaCT Multiphase from Siemens Healthineers. The syngo DynaCT Multiphase is a three-dimensional image acquisition technique employing multiple rotations of a C-arm system to acquire a multi-phasic 3-D representation of the brain and its perfusion. This technology, when combined with the RAPID platform’s CTP product, delivers a powerful imaging solution to the angio suite for acute stroke patients.
March 01, 2019 
iSchemaView announced that more than 575 stroke centers in 22 countries have selected the RAPID advanced imaging platform for cerebrovascular imaging, with 520 currently installed. RAPID technology assists physicians in the analysis of brain images using automated tools for CT ASPECTS, computed tomography (CT) angiography, CT perfusion, magnetic resonance (MR) diffusion and perfusion for more than 85,000 stroke cases per year. RAPID is also currently deployed in six multi-center clinical trials globally.
August 27, 2018 
iSchemaView has signed Diagnostic Imaging Australia (DIA) to be the exclusive distributor for the RAPID cerebrovascular imaging analysis platform in Australia and New Zealand. Hospitals and clinics that treat ischemic stroke in these countries will now have access to RAPID’s automated computed tomography perfusion (CTP), magnetic resonance (MR), CT angiography (CTA) and ASPECTS solutions, with support from DIA’s customer service specialists in the region.
July 13, 2018 
Cerebrovascular imaging analysis company iSchemaView received final clearance from the U.S. Food and Drug Administration (FDA) for Rapid CTA, the company’s 3-D imaging solution for computed tomography angiography. Rapid CTA is the newest addition to iSchemaView’s neuroimaging platform — including Rapid CTP and Rapid MRI — which is designed to provide physicians with fast, fully-automated and easy-to-interpret imaging that facilitates clinical decision making around cerebrovascular disease, such as stroke.
May 01, 2018